Apoptosis of activated CD8+/CD57+ T cells is induced by some combinations of anti-CD2 mAb. 1993

M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
Laboratoire d'Immunologie Cellulaire et de Transplantation, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.

Peripheral blood CD8+/CD57+ T cells display poor proliferative responses when stimulated with CD3 or CD2 in vitro, but can be induced to proliferate in the presence of exogenous IL-2. Although GT2+T11(1), a mitogenic anti-CD2 mAb pair, could synergize with IL-2 to induce sustained cell divisions in this population (as did immobilized OKT3), D66+T11(1), another anti-CD2 mAb pair, could only induce a small abortive proliferative response. All these antibodies were in contrast strongly mitogenic for CD8+/CD57- T cells. Assuming that D66+T11(1) were exerting inhibitory effects on CD8+/CD57+ T cells, we indeed found that such antibodies profoundly suppressed the anti-CD3 and IL-2-induced proliferation of those cells, but not that of CD8+/CD57- cells. CD2-mediated growth arrest was correlated with rapid cell death occurring within 2 h, once the cells had been submitted to D66+T11(1), and cells susceptible to the death signal were large cells committed in the cell cycle. D66+T11(1)-treated cells had the well-known ultrastructural form of apoptosis, and the DNA extracted from these cells showed the typical ladder pattern of DNA fragmentation accompanying this process. For apoptosis to occur, two anti-CD2 mAb had to be applied to the cells, one of them being D66, suggesting that the corresponding anti-CD2 mAb pairs were imposing on the CD2 molecule a particular conformational change appropriate to transduce a death signal. Notably, CD8+/CD57- T cells were largely resistant to apoptosis in the conditions just described. When exposed to anti-CD3 and IL-2 in primary and secondary cultures, CD8+/CD57+ T cells retained high viability, whereas in contrast, when exposed to D66+T11(1), important cell loss occurred, concomitant with apoptosis, illustrating the specificity of the CD2-derived death signal. Our results suggest that the expansion of CD8+/CD57+ T cells is critically dependent on the CD2 pathway which, according to the conformational change of the CD2 molecule and the activation state of the cells, will direct them either towards proliferation or towards cell death.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000945 Antigens, Differentiation, T-Lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function. Antigens, Differentiation, T-Cell,Differentiation Antigens, T-Cell,L3T4 Antigens,Leu Antigens, T-Lymphocyte,T-Cell Differentiation Antigens,T-Lymphocyte Differentiation Antigens,T6 Antigens,Antigens, Differentiation, T Lymphocyte,Differentiation Antigens, T Lymphocyte,Antigens, L3T4,Antigens, T-Cell Differentiation,Antigens, T-Lymphocyte Differentiation,Antigens, T-Lymphocyte Leu,Antigens, T6,Differentiation Antigens, T Cell,Differentiation Antigens, T-Lymphocyte,Leu Antigens, T Lymphocyte,T Cell Differentiation Antigens,T Lymphocyte Differentiation Antigens,T-Lymphocyte Leu Antigens
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
January 2017, Journal of immunology research,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
July 1996, International immunology,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
April 1988, Journal of immunology (Baltimore, Md. : 1950),
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
November 1999, Transplantation,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
March 1998, British journal of haematology,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
April 1998, Journal of immunology (Baltimore, Md. : 1950),
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
July 2008, The Journal of allergy and clinical immunology,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
August 1994, Journal of leukocyte biology,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
July 2001, European journal of immunology,
M Rouleau, and A Bernard, and O Lantz, and J P Vernant, and B Charpentier, and A Senik
June 2018, Oncology letters,
Copied contents to your clipboard!